Université De Nantes

Jacques Aubry

Jacques Barbet

Jean-Marie Mussini

Jean-Francois Chatal

Stephane Birkle

Stéphane Birkle

Beatrice Clemenceau

Assia Mezazigh Hami

Jean-François Chatal

Stéphane Supiot

The monoclonal antibodies that only recognize the O-acetylated form of the GD2 ganglioside, or fragments of the antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, the antibody or the fragment recognizing the O-acetylated GD2 molecules expressed by the tumoral cells and not recognizing the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. Also artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.

Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers

The invention relates to the use of monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of said antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, said antibody or said fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. The invention also relates to artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.

Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for treatment of certain cancers

Growing community of inventors

Nantes, France

Jacques Aubry